BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Watanabe R, Hashimoto M. Perspectives of JAK Inhibitors for Large Vessel Vasculitis. Front Immunol 2022;13:881705. [PMID: 35432355 DOI: 10.3389/fimmu.2022.881705] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Nash P. JAK inhibitors: new indication and emerging safety data in 2022. Nat Rev Rheumatol 2023;19:72-3. [PMID: 36536119 DOI: 10.1038/s41584-022-00891-4] [Reference Citation Analysis]
2 Watanabe R, Kiji M, Hashimoto M. Vasculitis associated with VEXAS syndrome: A literature review. Front Med 2022;9. [DOI: 10.3389/fmed.2022.983939] [Reference Citation Analysis]
3 Rizzo C, La Barbera L, Miceli G, Tuttolomondo A, Guggino G. The innate face of Giant Cell Arteritis: Insight into cellular and molecular innate immunity pathways to unravel new possible biomarkers of disease. Front Mol Med 2022;2. [DOI: 10.3389/fmmed.2022.933161] [Reference Citation Analysis]
4 Matsumoto K, Suzuki K, Yoshida H, Magi M, Kaneko Y, Takeuchi T. Longitudinal monitoring of circulating immune cell phenotypes in large vessel vasculitis. Autoimmun Rev 2022;21:103160. [PMID: 35926769 DOI: 10.1016/j.autrev.2022.103160] [Reference Citation Analysis]
5 Watanabe R, Hashimoto M. Pathogenic role of monocytes/macrophages in large vessel vasculitis. Front Immunol 2022;13:859502. [DOI: 10.3389/fimmu.2022.859502] [Reference Citation Analysis]
6 Watanabe R, Hashimoto M. Vasculitogenic T Cells in Large Vessel Vasculitis. Front Immunol 2022;13:923582. [DOI: 10.3389/fimmu.2022.923582] [Reference Citation Analysis]